Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Chong‐Rui Xu's publication output changed over time?
ScholarIQpublication output · 2007–2022
Output grew100% over the shown period — from 1 works in 2007 to 2 in 2022.
1
1
1
2
1
2
2
2
20072011201420172018202020212022
What are the most-cited papers on Chong‐Rui Xu?
ScholarIQmost cited works
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Yi‐Long Wu, Caicun Zhou, Chengping Hu, Jifeng Feng, Shun Lü, Yunchao Huang, Wěi Li, Mei Hou, Jian Hua Shi, Kye Young Lee, Chong‐Rui Xu, Dan Massey, Miyoung Kim, Yang Shi, Sarayut Lucien Geater
The Lancet Oncology. 20141,984 Citations
EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer
Zhong‐Yi Dong, Jia‐Tao Zhang, Si‐Yang Maggie Liu, Jian Su, Chao Zhang, Zhi Xie, Qing Zhou, Hai‐Yan Tu, Chong‐Rui Xu, Li‐Xu Yan, Yufa Li, Wen‐Zhao Zhong, Yi‐Long Wu
S2497914550. 2017448 CitationsOPEN ACCESS
Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy
Y.S. Li, Bo Jiang, Jin‐Ji Yang, X.C. Zhang, Zhou Zhang, J.Y. Ye, Wen‐Zhao Zhong, Hai‐Yan Tu, H.J. Chen, Z. Wang, Chong‐Rui Xu, B.C. Wang, Hao Du, Shaokun Chuai, Han Han‐Zhang, Jian Su, Qing Zhou, Xue‐Ning Yang, Wanting Guo, Hong‐Hong Yan, Y.H. Liu, Li‐Xu Yan, Biao Huang, Mei-Mei Zheng, Yi‐Long Wu
Annals of Oncology. 2018331 CitationsOPEN ACCESS
HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers
Bob T. Li, Flavia Michelini, Sandra Misale, Emiliano Cocco, Laura Baldino, Yanyan Cai, Sophie Shifman, Hai‐Yan Tu, Mackenzie L. Myers, Chong‐Rui Xu, Marissa S. Mattar, Inna Khodos, Megan Little, Besnik Qeriqi, Gregory Weitsman, Clare J. Wilhem, Alshad S. Lalani, Irmina Diala, Rachel A. Freedman, Nancy U. Lin, David B. Solit, Michael F. Berger, Paul R. Barber, Tony Ng, Michael Offin, James M. Isbell, David R. Jones, Helena A. Yu, Sheeno Thyparambil, Wei‐Li Liao, Anuja Bhalkikar, Fabiola Cecchi, David M. Hyman, Jason S. Lewis, Darren J. Buonocore, Alan L. Ho, Vicky Makker, Jorge S. Reis‐Filho, Pedram Razavi, Maria E. Arcila, Mark G. Kris, John T. Poirier, Ronglai Shen, Junji Tsurutani, Gary A. Ulaner, Elisa de Stanchina, Neal Rosen, Charles M. Rudin, Maurizio Scaltriti
Cancer Discovery. 2020295 CitationsOPEN ACCESS
Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma
Hao Sun, Si‐Yang Maggie Liu, Jiaying Zhou, Jintian Xu, Huang-Kai Zhang, Hong‐Hong Yan, Jiaojiao Huan, Pingping Dai, Chong‐Rui Xu, Jian Su, Yanfang Guan, Xin Yi, Rongshan Yu, Wen‐Zhao Zhong, Yi‐Long Wu
EBioMedicine. 2020255 CitationsOPEN ACCESS
Related on ScholarIQ
Guangdong Academy of Medical Sciences
Institution
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Paper
EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer
Paper
Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy
Paper
HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers
Paper
Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma
Paper